Vesugen (Lys-Glu-Asp) is a synthetic tripeptide from the Khavinson bioregulator series designed to normalize vascular endothelial function through tissue-specific gene regulation.
Category: Cardiovascular / Bioregulator. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only
Regulates endothelial gene expression to normalize vascular tone. Modulates endothelial nitric oxide production and provides anti-atherogenic activity through epigenetic mechanisms.
Safety considerations: Minimal side effects reported in available literature.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
Vesugen is a Khavinson bioregulator tripeptide (Lys-Glu-Asp) researched for vascular endothelial support and cardiovascular tissue maintenance in aging.
VESUGEN has been studied for: Endothelial function, Vascular health, Cardiovascular tissue support, Microcirculation. Khavinson bioregulator; vascular endothelial focus.
Tripeptide bioregulator that may interact with DNA in vascular endothelial cells, modulating gene expression related to angiogenesis, endothelial repair, and vascular tone.
Coverage on this site: Pinealon: Neuroprotective Tripeptide Research Guide.